Dr. Abdulla Mostafa is a neurosurgeon and a clinical reviewer on Biohack Blueprint's medical advisory board. His clinical practice and published research cover the areas he signs off on the site — traumatic brain injury and recovery outcomes, the mechanistic biology of the ageing central nervous system, the pharmacology of compounds that cross the blood-brain barrier, and the circadian pathway from retina to suprachiasmatic nucleus to pineal. His involvement here is editorial only.
His published work includes Prognostic Factors of Recovery and Discharge Outcome in Adults after Moderate Traumatic Brain Injury (ResearchGate) — a clinical prognostic study examining which factors predict functional recovery and discharge outcome in adults following moderate TBI. That kind of outcome-focused clinical research is the same lens he brings to reviewing longevity supplement literature: the difference between a marker moving and a patient benefiting is the whole question.
On product reviews, his job on the byline is to sign off on the mechanism and the evidence framing in the neurology, neurosurgery, sleep, circadian, and CNS-relevant sections — flagging anything that overstates what the published trials show, and pushing back on marketing language that would not survive peer review. The commercial framing of the review — the DoNotAge affiliate relationship, the BB10 code, the buy-through recommendation — is Biohack Blueprint's editorial decision, not his.
Independence. Dr. Mostafa has no commercial relationship with DoNotAge. He is not paid by the manufacturer, holds no equity in the company, and receives no product, discount, or consideration in exchange for his clinical review. He contributes his review time to Biohack Blueprint pro bono and receives no compensation from Biohack Blueprint or DoNotAge for the review work itself. If his read of the evidence is that a claim does not hold up, that is what appears on the page.
